Zacks Investment Research Downgrades Chiasma (NASDAQ:CHMA) to Hold
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
A number of other analysts have also issued reports on CHMA. Cantor Fitzgerald set a $18.00 target price on Chiasma and gave the stock a buy rating in a research report on Friday, September 13th. HC Wainwright reaffirmed a buy rating and set a $11.00 target price on shares of Chiasma in a research report on Tuesday, July 23rd. Piper Jaffray Companies started coverage on Chiasma in a research report on Wednesday, July 31st. They set an overweight rating and a $11.00 target price on the stock. ValuEngine lowered Chiasma from a buy rating to a hold rating in a research report on Thursday, August 1st. Finally, Brookline Capital Management reaffirmed a buy rating on shares of Chiasma in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $12.40.
Chiasma (NASDAQ:CHMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Equities research analysts anticipate that Chiasma will post -1.09 EPS for the current fiscal year.
In other Chiasma news, Director Scott Minick bought 9,818 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were acquired at an average cost of $5.19 per share, with a total value of $50,955.42. Following the completion of the transaction, the director now owns 62,531 shares in the company, valued at $324,535.89. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $6.35, for a total value of $63,500.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at $63,500. The disclosure for this sale can be found here. 8.30% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Quantitative Systematic Strategies LLC acquired a new position in Chiasma in the second quarter worth about $100,000. Cubist Systematic Strategies LLC grew its stake in Chiasma by 35.4% in the second quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,722 shares in the last quarter. Citadel Advisors LLC acquired a new position in Chiasma in the second quarter worth about $145,000. Invesco Ltd. acquired a new position in Chiasma in the second quarter worth about $186,000. Finally, Wells Fargo & Company MN acquired a new position in Chiasma in the second quarter worth about $237,000. Institutional investors and hedge funds own 52.97% of the company’s stock.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
See Also: What is a stock portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.